Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-019585
Filing Date
2025-07-09
Accepted
2025-07-09 17:16:55
Documents
1
Period of Report
2025-07-01

Document Format Files

Seq Description Document Type Size
1 form3-07092025_090752.html 3  
1 form3-07092025_090752.xml 3 1687
  Complete submission text file 0001415889-25-019585.txt   3208
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Issuer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1764 TUSCANY WAY BRENTWOOD, TN 37027
Business Address
Jahr Robert Charles (Reporting) CIK: 0002076177 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37759 | Film No.: 251114298